Atea Pharmaceuticals Inc — Quarterly Financial Statistics (NASDAQ:AVIR) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -30.4 M-30.56 M-32.87 M-40.38 M-28.22 M -132.03 M Cash from investing activities -3.37 M85.61 M15.29 M41.3 M46.59 M 188.79 M Cash from financing activities 0-347 K-14.09 M-11.3 M0 -25.75 M Free cash flow -30.4 M-30.56 M-32.87 M-40.38 M-28.22 M -132.03 M

News

Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Arcellx (NASDAQ:ACLX), Atea Pharmaceuticals (NASDAQ:AVIR)

Atea Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:AVIR) 2026-03-05

Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript

Atea Q4 2025 slides: pivotal HCV Phase 3 data due mid-2026

Earnings call transcript: Atea Pharmaceuticals Q4 2025 sees stock rise despite EPS miss

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:AVIR) 2026-01-19

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Atea’s HCV treatment regimen phase 3 results expected mid-2026

Atea Pharmaceuticals: Best-In-Class HCV Cure With Pivotal Readouts In 2026 (NASDAQ:AVIR)

Atea completes enrollment in HCV treatment phase 3 trial

Atea Pharmaceuticals, Inc. 2025 Q3 - Results - Earnings Call Presentation (NASDAQ:AVIR) 2025-11-14

Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript